🙌 The ESMO GI Congress 2025 is live — in Barcelona, and online! #ESMOGI25 brings global experts together to advance GI oncology from 2–5 July. Let’s get started!
🔗 buff.ly/5V8eZ1m
#ESMOGI25: New combinations show promise in #HCC. Favourable responses were seen with irpagratinib plus atezolizumab in FGF19+ disease. STRIDE had acceptable safety in poor-prognosis patients in the SIERRA #ClinicalTrial.
Read the #ESMODailyReporter
🔗 ow.ly/Nxug50WjJIJ
#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
June is #UterineCancerAwareness month.
A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.
📣 Get ready to submit your research to EMUC25!
⏰ Abstract deadline coming up: 1 August 2025.
🔗 buff.ly/leSW7AP
HCC micro learning 🎓
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
FLOT + durvalumab new perioperative treatment of localised gastric cancer
Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky
Confirmation of the pronostic role of positive ctDNA in resected colon cancer... a large US study
ASCO meeting starting today in Chicago
The rate of dementia caused by Alzheimer’s disease and other conditions is rising rapidly in China and will remain high if preventive measures are not taken
https://go.nature.com/43ktPB5
📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines
🔗https://buff.ly/Mybc2Nq
@ducreuxmichel.bsky.social
📰 Des femmes affrontent leur "risque augmenté" de #cancer du sein grâce à la prévention personnalisée.
Découvrez le programme #Interception proposé à @gustaveroussy.fr, dans une dépêche @afpfr.bsky.social publiée dans @sciencesetavenir.bsky.social ⤵
Kicking off #CCEAM25 at @nkinl.bsky.social! Looking forward to two days of collaboration, networking, and insightful discussions.
@vhio.bsky.social @nct-heidelberg.bsky.social @dkfz.bsky.social @gustaveroussy.fr @ki.se
@crukcamcentre.bsky.social
Our study is now out in JCO print edition!
There's still something special to getting to hold a physical copy of what you did. Gotta take your wins where you can, these days.
Full article here:
ascopubs.org/doi/full/10....
@ascocancer.bsky.social
We are committed to advancing policies that improve patient access to high-quality cancer care. We continue to collaborate with all stakeholders to address existing barriers and ultimately improve cancer care for those in need.
In the past two decades, substantial advancements have been made in cancer research and care.
From innovative treatments to improving access to care globally, discover how oncology research is shaping the future of cancer care.
🎥 tinyurl.com/5a642pwk #OncSky #MedSky
🚀 We have launched our 1st Clinical Series of 2025 at the EASL Liver Cancer Summit 2025 in Paris! 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐓𝐫𝐚𝐜𝐭 𝐂𝐚𝐧𝐜𝐞𝐫𝐬 (BTCs)
🔬BTCs are rising in incidence & mortality across Europe.
Explore key findings & recommendations in our infographic & read the Series here
thelancet.com/infographics...
Urgent action is needed to scale-up cancer prevention and care services.
Cancer registries can play a crucial role in this.
Ahead of #WorldCancerDay, our Editorial explores the benefits and challenges of cancer registries in global cancer care: tinyurl.com/ywpr6e37
🔴 Eduardo Terán, from VHIO's Upper Gastrointestinal & Endocrine Tumor Group, presented the poster "Molecular profiling of a gastroesophageal adenocarcinoma multicohort using next-generation sequencing" at #ASCOGI. 🩺🔬
New research just presented at #GI25: BREAKWATER study finds 1L EC + mFOLFOX6 improves outcomes in BRAFV600E-mutant mCRC, offering new SOC: brnw.ch/21wQfxm
#ASCODailyNews #GICSM
Nivolumab + Ipilimumab better than nivoluma in the treatment of metastatic MSI patients. Results presented by T André at GI ASCO. Significant improvement in PFS
Aspirin 160 mg daily reduced by 50% the recurrence rate of colorectal cancer patients with PI3K mutated tumours
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: brnw.ch/21wQeCg
#ASCODailyNews #GICSM
What an incredible Day 2 at #GI25! Filled with thought-provoking sessions and insightful research, the energy and passion of this community are truly unstoppable. We can’t wait to connect with everyone again for Day 3!
🧪 Scientists have tracked microplastics in mice, finding them ingested by immune cells, obstructing brain blood vessels, and reducing mobility. Published in Science Advances, this raises concerns about human health impacts. 🩺 www.nature.com/articles/d41...
I am very happy to have left X. I hope to find as many colleagues as soon as possible on this social network, which suits me better...
Happy to find you on Bluesky!!!
